These products have not received the safety and quality review of the FDA, and have not adequately been tested on humans like other more rigorously tested products like GLP-1 drugs
BPC-157's gastroprotective properties have theoretical appeal alongside semaglutide, given that GI side effects are semaglutide's most common adverse event
Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
Menopause is a natural phase in a womans life, marked by significant hormonal changes that can bring about various physical and emotional challenges
Preservative allows for multiple safe withdrawals
All applications require individual assessment BPC-157 is not a one-size-fits-all treatment